|
**Overview**: **Immune Deficiency Panel 1 Profile****Introduction**: The Immune Deficiency Panel 1 Profile is a diagnostic tool designed to screen for immune deficiencies using serum samples. Associated with conditions like common variable immunodeficiency and severe combined immunodeficiency, these disorders present with recurrent infections, fatigue, and severe complications if untreated, particularly in individuals with suspected immune issues. Per the 2023 Immunology guidelines, the test employs immunology with immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for immune system evaluation in clinical settings. This diagnostic falls under immune system evaluation and targets individuals with suspected immune deficiencies, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Imm Def 1 Pfl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by immunology labs, this test advanced immune deficiency screening.**Purpose**: The test screens for 12 parameters including IgG to guide immune assessment, assess immunoglobulin and complement levels, and inform treatment and prevention strategies.**Test Parameters**: 1. IgG, 2. IgA, 3. IgM, 4. IgE, 5. C3, 6. C4, 7. CH50, 8. CD4 Count, 9. CD8 Count, 10. CD19 Count, 11. CD56 Count, 12. Total Lymphocyte Count.**Pretest Condition**: No fasting required; patients should report recurrent infections, fatigue, or recent immune symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on recurrent infections, fatigue, prior immune reactions, or family history of immunodeficiency, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated immune deficiencies including sepsis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent immunosuppressive therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible immune deficiencies, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in immunology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Flow cytometry or genetic testing for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Immunology Guidelines 2023, Journal of Allergy and Immunology 2024, Biochemistry 2025. |
